OTCMKTS:EVTCY - Evotec Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$61.00
▲ +1.15 (1.92%)
1 month | 3 months | 12 months
Get New Evotec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVTCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVTCY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Evotec in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $61.00.
Buy
The current consensus among 3 investment analysts is to buy stock in Evotec. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/20/2020Royal Bank of CanadaReiterated RatingOutperform
i
9/10/2020Royal Bank of CanadaInitiated CoverageOutperform
i
9/1/2020CitigroupInitiated CoverageBuy
i
3/12/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
8/21/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
i
4/10/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
7/27/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
11/8/2017DZ BankReiterated RatingSell
i
8/17/2017DZ BankReiterated RatingSell
i
8/10/2017DZ BankReiterated RatingSell
i
7/31/2017DZ BankReiterated RatingSell
i
7/25/2017Roth CapitalReiterated RatingBuy
i
Rating by M. Higgins at Roth Capital
7/12/2017DZ BankReiterated RatingSell
i
6/6/2017Berenberg BankDowngradeBuy ➝ Hold
i
5/20/2017Berenberg BankReiterated RatingBuy
i
5/11/2017Berenberg BankReiterated RatingBuy$85.00 ➝ $80.00
i
5/10/2017Berenberg BankReiterated RatingBuy
i
5/3/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
i
4/3/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
i
3/31/2017DZ BankReiterated RatingSell
i
3/31/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutral
i
3/30/2017DZ BankReiterated RatingSell
i
2/17/2017DZ BankReiterated RatingNeutral
i
2/10/2017DZ BankReiterated RatingNeutral
i
1/10/2017DZ BankReiterated RatingNeutral
i
12/9/2016DZ BankReiterated RatingBuy
i
11/18/2016Deutsche Bank AktiengesellschaftReiterated RatingNeutral
i
10/25/2016DZ BankReiterated RatingBuy
i
7/11/2016DZ BankReiterated RatingBuy
i
5/11/2016Deutsche Bank AktiengesellschaftReiterated RatingNeutral
i
4/8/2016DZ BankReiterated RatingBuy
i
(Data available from 11/30/2015 forward)
Evotec logo
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; and a drug discovery research collaboration with HitGen Inc. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: $61.00
$60.25
$61.00

50 Day Range

MA: $55.90
$51.90
$59.85

52 Week Range

Now: $61.00
$40.42
$61.00

Volume

700 shs

Average Volume

712 shs

Market Capitalization

$4.99 billion

P/E Ratio

160.53

Dividend Yield

N/A

Beta

1.1